NRIX · Nurix Therapeutics, Inc.
$26.95
+0.68 (+2.59%)
At close · Aug 25
Market Cap
$2.75B
Shares
103.78M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$83.98M
+54%
FY2025
Net Income
-$264.46M
-36.6%
FY2025
Operating Margin
-340.16%
+50.4pp
FY2025
Diluted EPS
-$3.05
-5.9%
FY2025
Operating Cash Flow
-$249.47M
-44.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $36.77M | $83.98M | $54.55M | $76.99M | $38.63M | $29.75M | $17.82M | $31.12M | |
| $340.93M | $316.9M | $221.63M | $189.15M | $184.5M | $116.43M | $66.49M | $45.03M | |
| $57.01M | $52.74M | $45.94M | $42.9M | $38M | $31.2M | $16.31M | $8.33M | |
| — | $8.74M | $9.32M | $7.53M | $5.35M | $2.79M | $2.18M | $2.35M | |
| $397.95M | $369.65M | $267.58M | $232.05M | $222.49M | $147.64M | $82.8M | $53.35M | |
| -$361.18M | -$285.67M | -$213.03M | -$155.06M | -$183.87M | -$117.89M | -$64.98M | -$22.24M | |
| — | -340.16% | -390.52% | -201.41% | -476.01% | -396.26% | -364.66% | -71.46% | |
| — | -$276.93M | -$203.71M | -$147.53M | -$178.52M | -$115.1M | -$62.8M | -$19.88M | |
| — | -$263.7M | -$193.3M | -$143.95M | -$180.36M | -$117.06M | -$63.78M | -$21.46M | |
| -$271K | $760K | $270K | $0 | $0 | $131K | -$20.54M | $239K | |
| -$341.35M | -$264.46M | -$193.57M | -$143.95M | -$180.36M | -$117.19M | -$43.24M | -$21.7M | |
| — | -314.9% | -354.85% | -186.98% | -466.93% | -393.93% | -242.66% | -69.74% | |
| -$341.48M | -$264.5M | -$192.76M | -$140.28M | -$184.07M | -$117.89M | -$43.15M | -$21.7M | |
| USD/shares | — | -$3.05 | -$2.88 | -$2.65 | -$3.71 | -$2.73 | — | — |
| USD/shares | — | -$3.05 | -$2.88 | -$2.65 | -$3.71 | -$2.73 | — | — |
| shares | — | 86.67M | 67.12M | 54.34M | 48.61M | 42.9M | 15.67M | 3.29M |
| shares | — | 86.67M | 67.12M | 54.34M | 48.61M | 42.9M | 15.67M | 3.29M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 8.18×
EV/EBIT
—
Peer median 16.82×
P/E (TTM)
—
Peer median 17.76×
Peer medians compare against the 243 similar-size Biotechnology companies (of 533 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Collaboration Revenue | $53,980,000 | $54,549,000 | $56,987,000 | $38,627,000 |
| License Revenue | $30,000,000 | $0 | $20,000,000 | $0 |
Key facts
CIK
1549595
CUSIP
67080M103
13F (30d)
196 filings
190 filers
Visit website
Investor relations